International health · 2025
Impact of evidence-based programmatic adaptations in addressing the persistence and recrudescence of trachoma in Kajiado County, Kenya.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eshitemi Samuel O, Senyonjo Laura G, Shiraho Esther A, Chailloux Alexandre, Watitu Titus, Omondi Wyckliff P, Njenga Sammy M, Kamuyu Michael K, Chege Moses, Martin Diana L, Gwyn Sarah, Harding-Esch Emma, Otinda Peter, Barasa Ernest, Oenga Rebecca
Аннотация
BACKGROUND: Confirmatory trachoma-plus surveys conducted in 2021 revealed persistent and recrudescent trachoma transmission in Kajiado West, South and Central subcounties. These findings prompted targeted investigations and programmatic adaptations to improve intervention effectiveness.
METHODS: Mass drug administration (MDA) coverage improvements were validated through Coverage Evaluation Surveys (CESs). Impact was monitored via prevalence surveys from 2021 to 2024, which included ocular swabs and dried blood spots (DBS) from children. Ocular swabs were tested for Chlamydia trachomatis (Ct) using GeneXpert IV PCR, while DBS were analysed for anti-Pgp3 antibodies using a multiplex bead assay.
RESULTS: CESs showed significant increases in MDA coverage: Kajiado West (56.9% to 88.2%), South (81.2% to 95.3%) and Central (69.3% to 95.3%). Trachomatous inflammation-follicular prevalence declined in all subcounties-Kajiado West (13.8% to 6.6%), South (8.1% to 5.2%), Central (18.0% to 8.0%)-and Ct infection rates dropped below 1%. Seroconversion rate trends varied, with increases in West and Central and a decrease in South.
CONCLUSIONS: The programmatic adaptations were effective in achieving high treatment coverage and in reducing active trachoma and infection, with varying trends in transmission dynamics. This resulted in major progress towards elimination of trachoma and areas with residual infection requiring closer monitoring to sustain progress.
METHODS: Mass drug administration (MDA) coverage improvements were validated through Coverage Evaluation Surveys (CESs). Impact was monitored via prevalence surveys from 2021 to 2024, which included ocular swabs and dried blood spots (DBS) from children. Ocular swabs were tested for Chlamydia trachomatis (Ct) using GeneXpert IV PCR, while DBS were analysed for anti-Pgp3 antibodies using a multiplex bead assay.
RESULTS: CESs showed significant increases in MDA coverage: Kajiado West (56.9% to 88.2%), South (81.2% to 95.3%) and Central (69.3% to 95.3%). Trachomatous inflammation-follicular prevalence declined in all subcounties-Kajiado West (13.8% to 6.6%), South (8.1% to 5.2%), Central (18.0% to 8.0%)-and Ct infection rates dropped below 1%. Seroconversion rate trends varied, with increases in West and Central and a decrease in South.
CONCLUSIONS: The programmatic adaptations were effective in achieving high treatment coverage and in reducing active trachoma and infection, with varying trends in transmission dynamics. This resulted in major progress towards elimination of trachoma and areas with residual infection requiring closer monitoring to sustain progress.